For Immediate Release: May 27, 2015

Mary Kuramoto
513-579-9911 x2523

Medpace Continues “The Power of Giving” Campaign at ASCO Campaign focuses on cancer research and support charitable organizations

CINCINNATI, OH — (May 27, 2015) – Medpace is continuing its “The Power of Giving” campaign at ASCO this week. The campaign was introduced earlier this year and aligns with the company’s key therapeutic and specialty areas in which it designs and executes clinical trials for drug, biologic and medical device sponsors. With extensive experience and expertise in hematology/oncology, Medpace is inviting ASCO attendees stop by booth 12063 to “choose a charity” to which a $5 contribution will be made. A maximum of $5000 will be donated to each charity at the end of the year.

ASCO attendees can designate one of these three charities to receive a donation:

“The Power of Giving campaign lets people directly participate in the company’s mission to accelerate the global development of safe and effective medical therapeutics, while also bringing attention to the key therapeutic and specialty areas where we have deep expertise and experience,” explained Todd Meyers, Vice-President Business Development at Medpace. “Rather than giving out the typical branded items at conferences, we believe participants will appreciate the opportunity to support a charity that helps fund important clinical research and support patients and families afflicted with disease.”

Medpace offers a unique physician-driven approach to clinical research. By embedding medical, scientific, and regulatory expertise throughout trial design and execution, Medpace has earned a reputation for adeptly managing complex and challenging clinical studies. The company shares its unique 20+-year history and approach to clinical research through its “Power of X: Experts, Experience and Execution” campaign.

The Power of Giving Campaign will continue throughout the year at conferences such as ASCO, DIA and others where Medpace is a sponsor.


Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information, please visit